Previous 10 | Next 10 |
Can-Fite BioPharma's ( NYSE: CANF ) oral drug piclidenoson helped reduce severity of symptoms compared to placebo, but failed to beat Amgen's ( AMGN ) Otezla in adult patients with moderate to severe plaque psoriasis in a phase 3 trial. Plaque psoriasis cau...
Phase III COMFORT™ study met its primary endpoint with statistically significant improvement and Piclidenoson had an excellent safety profile Can-Fite has licensing deals for the marketing of Piclidenoson for the treatment of Psoriasis in multiple global regions...
CF602’s unique mechanism of action enables potential treatment of diabetic patients and may offer an alternative to PDE5 (Viagra, Cialis, Levitra, and Stendra) non-responders accounting for 30-35% of the $3.6 billion ED market Patents granted in numerous healthc...
Data suggest Piclidenoson and Namodenoson could potentially be the first A3AR agonists to achieve FDA approval and provide clinicians with new oral and safe drugs in the arsenal for fighting psoriasis, liver cancer, and NASH Can-Fite is a global leader in the developme...
Can-Fite Biopharma press release (NYSE:CANF): Q1 GAAP EPS of $0.00 beats by $0.14. Revenue of $0.2M (+33.3% Y/Y) in-line. For further details see: Can-Fite Biopharma GAAP EPS of $0.00 beats by $0.14, revenue of $0.2M in-line
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended March 31, 2022. Corporate...
Phase IIb NASH study is currently enrolling patients; Phase IIa met endpoints including reduced liver fat content Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addres...
Namodenoson induced complete response and cleared all cancer lesions in advanced liver cancer patient in Phase II study Pivotal Phase III trial for the treatment of liver cancer is now open for the recruitment of patients Can-Fite BioPharma Ltd . (NYS...
Can-Fite (NYSE:CANF) said it was developing a topical psoriasis treatment with its psoriasis oral drug candidate Piclidenoson. The Company’s said that in a preclinical trial, daily treatment with topical Piclidenoson significantly inhibited the disease as measured by the psoriasis area...
Topical psoriasis treatments account for 42% of the $11.37 billion psoriasis drug market Topline results from Phase III oral Piclidenoson study expected Q2 2022 Piclidenoson has been out-licensed for the systemic indication of psoriasis in certain major mar...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...